Painchek (ASX:PCK)
ASX announcement history & article coverage
Transparent by design.
Announcments by Painchek (ASX:PCK) are listed here, whether we covered it or not. Where we've written an article, you'll see it linked directly. Where we haven't, the filing is still shown so nothing is hidden from view. If you think a particular announcement deserved editorial coverage and was overlooked, you can flag it for review and our team will take a look.
Investor Webinar Invite
Resignation of Non-Executive Director
Appendix 4E and Financial Report
PainChek Investor Webinar
Update - Notification regarding unquoted securities - PCK
Change of Director's Interest Notice x 4
Quarterly Activities/Appendix 4C Cash Flow Report
PainChek reports 5.9% ARR growth, first US commercial deployments, and improved cash flow
PainChek receives $1.123 million R&D tax incentive refund
PainChek receives $1.123 million R&D tax incentive refund to support product development and US market entry
US MedTech leader Karen Holzberger appointed CEO
PainChek appoints Karen Holzberger as CEO to drive US market growth
Final Director's Interest Notice
CEO Transition
PainChek CEO Philip Daffas Steps Down; COO Andy Hoggan Named Interim CEO
Notification of cessation of securities - PCK
Change of Director's Interest Notice x5
Notification regarding unquoted securities - PCK